Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied.

The IL-2:IL-2R protein-protein interaction is of central importance to both healthy and diseased immune responses, and is one of the earliest examples of successful small-molecule inhibitor discovery against this target class. Drug-like inhibitors of IL-2 have been identified through a combination of fragment discovery, structure-based design, and medicinal chemistry; this discovery approach illustrates the importance of using a diverse range of complementary screening methods and analytical tools to achieve a comprehensive understanding of molecular recognition. The IL-2 story also provides insight into the dynamic nature of protein-protein interaction surfaces, their potential druggability, and the physical and chemical properties of effective small-molecule ligands. These lessons, from IL-2 and similar discovery programs, underscore an increasing awareness of the principles governing the development of drugs for protein-protein interactions.

[1]  W. Greene,et al.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen , 1984, The Journal of experimental medicine.

[2]  M. Stahl,et al.  Chemical Fragment Spaces for de novo Design. , 2007 .

[3]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[4]  K. Calis,et al.  Recombinant interleukin-2: a biological response modifier. , 1991, Clinical pharmacy.

[5]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[6]  A. Ridderstad,et al.  Cytokines in rheumatoid arthritis. , 1991, Annals of medicine.

[7]  Volkhard Helms,et al.  What induces pocket openings on protein surface patches involved in protein–protein interactions? , 2009, J. Comput. Aided Mol. Des..

[8]  H. Morris,et al.  Amino acid sequence and post-translational modification of human interleukin 2. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[9]  F. Hagemeister,et al.  Denileukin diftitox: a novel immunotoxin , 2009, Expert opinion on biological therapy.

[10]  R. Lier,et al.  Common γ chain cytokines: Dissidence in the details , 2007 .

[11]  B. Rouse,et al.  Regulatory Cells and Infectious Agents: Détentes Cordiale and Contraire , 2004, The Journal of Immunology.

[12]  Chris Abell,et al.  Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.

[13]  Xuetao Cao,et al.  Interleukin-17 and its expanding biological functions , 2010, Cellular and Molecular Immunology.

[14]  D. Delgado,et al.  The promise of C2, Simulect, and Certican in heart transplantation. , 2004, Transplantation proceedings.

[15]  K. McKeage,et al.  Basiliximab: a review of its use as induction therapy in renal transplantation. , 2010, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[16]  J. Lear,et al.  A new data analysis method to determine binding constants of small molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. , 2001, Analytical biochemistry.

[17]  Nir London,et al.  The structural basis of peptide-protein binding strategies. , 2010, Structure.

[18]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[19]  M. Goldsmith,et al.  The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Waldmann,et al.  The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases , 2002, Arthritis research.

[21]  N. Tanaka,et al.  Cloning of the gamma chain of the human IL-2 receptor. , 1992, Science.

[22]  Peter Ertl,et al.  Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions , 2009, J. Cheminformatics.

[23]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[24]  M. Masri The mosaic of immunosuppressive drugs. , 2003, Molecular immunology.

[25]  D. Fry,et al.  NMR characterization of interleukin‐2 in complexes with the IL‐2Rα receptor component, and with low molecular weight compounds that inhibit the IL‐2/IL‐Rα interaction , 2003, Protein science : a publication of the Protein Society.

[26]  P. Sellier,et al.  Interleukin-2 therapy in patients with HIV infection. , 2010, The New England journal of medicine.

[27]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[28]  Dorothea Busse,et al.  Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments , 2010, Proceedings of the National Academy of Sciences.

[29]  N. Tanaka,et al.  The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. , 1996, Annual review of immunology.

[30]  Xavier Morelli,et al.  Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets. , 2009, Combinatorial chemistry & high throughput screening.

[31]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[32]  T. van Gelder,et al.  Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? , 2004, Drugs.

[33]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[34]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[35]  S. Feng,et al.  Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys. , 2004, Transplantation proceedings.

[36]  A. Balcerska,et al.  Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[37]  J. Thornton,et al.  A method for localizing ligand binding pockets in protein structures , 2005, Proteins.

[38]  M. Sayegh,et al.  The role of costimulatory molecules as targets for new immunosuppressives in transplantation. , 2000, Current opinion in urology.

[39]  D. Brennan,et al.  Current and Future Immunosuppressive Strategies in Renal Transplantation , 2004, Pharmacotherapy.

[40]  A. Rudensky,et al.  Control of regulatory T cell lineage commitment and maintenance. , 2009, Immunity.

[41]  Y. Yamamura,et al.  The IL-2 receptor beta-chain (p70). Ligand binding ability of the cDNA-encoding membrane and secreted forms. , 1990, Journal of immunology.

[42]  Cornel Catana,et al.  Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening , 2006, Proteins.

[43]  C. Ponticelli Cyclosporine: From Renal Transplantation to Autoimmune Diseases , 2005, Annals of the New York Academy of Sciences.

[44]  B. Nashan The interleukin-2 inhibitors and their role in low-toxicity regimens. , 1999, Transplantation proceedings.

[45]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Bielekova,et al.  Monoclonal antibodies in MS , 2010, Neurology.

[47]  Roderick E Hubbard,et al.  Fragment-based ligand discovery. , 2009, Molecular interventions.

[48]  E. Geissler,et al.  mTOR, Cancer and Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[49]  S. Gaffen Signaling domains of the interleukin 2 receptor. , 2001, Cytokine.

[50]  Matthew A Burchill,et al.  Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. , 2007, Immunology letters.

[51]  D. Fattori,et al.  Fragment-Based Approach to Drug Lead Discovery , 2008, Drugs in R&D.

[52]  Suzanne C Brewerton,et al.  The use of protein-ligand interaction fingerprints in docking. , 2008, Current opinion in drug discovery & development.

[53]  David C Fry,et al.  Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.

[54]  Jonathan C. Fuller,et al.  Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.

[55]  M. Bevan,et al.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. , 2010, Immunity.

[56]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[57]  Marc-André Delsuc,et al.  Biophysical techniques for ligand screening and drug design. , 2009, Current opinion in pharmacology.

[58]  Dima Kozakov,et al.  Convergence and combination of methods in protein-protein docking. , 2009, Current opinion in structural biology.

[59]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[60]  Christopher D. Thanos,et al.  Hot-spot mimicry of a cytokine receptor by a small molecule , 2006, Proceedings of the National Academy of Sciences.

[61]  J. Dunn Review of immunosuppressive drug therapy in uveitis , 2004, Current opinion in ophthalmology.

[62]  P. Jhurani,et al.  Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. , 1989, Science.

[63]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[64]  Kristin E. D. Coan,et al.  Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding , 2009, Journal of medicinal chemistry.

[65]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[66]  A Wlodawer,et al.  Structural comparisons among the short-chain helical cytokines. , 1994, Structure.

[67]  T. Waldmann,et al.  Phorbol diester induces expression of Tac antigen on human acute T lymphocytic leukemic cells. , 1984, Journal of immunology.

[68]  Maria A Miteva,et al.  Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.

[69]  S. Sandrini Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review , 2005, Clinical transplantation.

[70]  S. Stauffer,et al.  Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. , 2007, Current topics in medicinal chemistry.

[71]  Iain B McInnes,et al.  Evidence that cytokines play a role in rheumatoid arthritis. , 2008, The Journal of clinical investigation.

[72]  A. Church Clinical advances in therapies targeting the interleukin-2 receptor. , 2003, QJM : monthly journal of the Association of Physicians.

[73]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[74]  J. Tavernier,et al.  Cloning and structure of the human interleukin 2 chromosomal gene. , 1983, The EMBO journal.

[75]  M. Randal,et al.  Potent small-molecule binding to a dynamic hot spot on IL-2. , 2003, Journal of the American Chemical Society.

[76]  Sylvia E Kim Daclizumab Treatment for Multiple Sclerosis , 2009, Pharmacotherapy.

[77]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[78]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[79]  Daniel A Erlanson,et al.  Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. , 2004, Current opinion in chemical biology.

[80]  P. Gregersen,et al.  Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.

[81]  Roland Martin Humanized Anti-CD25 Antibody Treatment with Daclizumab in Multiple Sclerosis , 2007, Neurodegenerative Diseases.

[82]  Bert L. de Groot,et al.  Ligand docking and binding site analysis with PyMOL and Autodock/Vina , 2010, J. Comput. Aided Mol. Des..

[83]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[84]  R. V. van Montfort,et al.  Structure-based design of molecular cancer therapeutics. , 2009, Trends in biotechnology.

[85]  V. Fung,et al.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. , 1994, Science.

[86]  J. Watson,et al.  Molecular Characterization of Interleukin 2 , 1982, Federation proceedings.

[87]  K. Audouze,et al.  Emerging classes of protein-protein interaction inhibitors and new tools for their development. , 2004, Current opinion in chemical biology.

[88]  G. Ju,et al.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Mark Whittaker,et al.  The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..

[90]  R. Nussinov,et al.  Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[91]  V. Helms,et al.  Transient pockets on protein surfaces involved in protein-protein interaction. , 2007, Journal of medicinal chemistry.

[92]  C. Poirier Promise of Neoral C2, basiliximab, and everolimus in lung transplantation. , 2004, Transplantation proceedings.

[93]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[94]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[95]  G. Crabtree,et al.  Molecular cloning and expression of cDNAs for the human interleukin-2 receptor , 1984, Nature.

[96]  A. Feller,et al.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.

[97]  Harald Schwalbe,et al.  Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.

[98]  W. Leonard,et al.  The role of Stat5a and Stat5b in signaling by IL-2 family cytokines , 2000, Oncogene.

[99]  A. Le Moine,et al.  Interleukin 17-producing T helper cells in alloimmunity. , 2009, Transplantation reviews.

[100]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[101]  Michelle R. Arkin,et al.  Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2 , 2002 .

[102]  G. Tsokos,et al.  Transcriptional regulation of IL-2 in health and autoimmunity. , 2009, Autoimmunity reviews.

[103]  David L Mobley,et al.  Quantifying Correlations Between Allosteric Sites in Thermodynamic Ensembles. , 2009, Journal of chemical theory and computation.

[104]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[105]  M. Arkin,et al.  Identification of nonpeptidic small-molecule inhibitors of interleukin-2. , 2005, Bioorganic & medicinal chemistry letters.

[106]  P. Karakiewicz,et al.  Treatment of metastatic renal cell carcinoma , 2010, Nature Reviews Urology.

[107]  A. Balcerska,et al.  Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review , 2008 .

[108]  G. Chinnadurai,et al.  BH3-only proteins in apoptosis and beyond: an overview , 2008, Oncogene.

[109]  S. Brouard,et al.  Interleukin 7 receptor α as a potential therapeutic target in transplantation , 2009, Archivum Immunologiae et Therapiae Experimentalis.

[110]  Mitchell A. Avery,et al.  Targeting the BH3 Domain Mediated Protein-Protein Interaction of Bcl-xL through Virtual Screening , 2010, J. Chem. Inf. Model..

[111]  G. Siegal,et al.  Fragment‐Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity , 2007, ChemMedChem.

[112]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[113]  T. Olencki,et al.  Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. , 1997, Journal of immunotherapy.

[114]  K. Garcia,et al.  Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. , 2005, Science.

[115]  Kendall A. Smith,et al.  Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. , 2010, Immunity.

[116]  T. Taniguchi,et al.  IL‐2 Signaling Involves Recruitment and Activation of Multiple Protein Tyrosine Kinases by the IL‐2 Receptor a , 1995, Annals of the New York Academy of Sciences.

[117]  D. Mckay,et al.  Three-dimensional structure of interleukin-2. , 1987, Science.

[118]  Helgi B. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[119]  Scott P. Brown,et al.  Effects of Conformational Dynamics on Predicted Protein Druggability , 2006, ChemMedChem.

[120]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[121]  Heather A Carlson,et al.  Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. , 2007, Journal of the American Chemical Society.

[122]  A. Kirk,et al.  A New Look at Blockade of T‐cell Costimulation: A Therapeutic Strategy for Long‐term Maintenance Immunosuppression , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[123]  M. Parkes,et al.  Contribution of the IL‐2 and IL‐10 genes to inflammatory bowel disease (IBD) susceptibility , 1998, Clinical and experimental immunology.

[124]  T. Taniguchi,et al.  Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. , 1989, Science.

[125]  Yongbo Hu,et al.  Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy , 2009, J. Chem. Inf. Model..

[126]  Thomas D. Goddard,et al.  Visualization software for molecular assemblies. , 2007, Current opinion in structural biology.

[127]  W. Koltun,et al.  THE EFFECT OF ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY ON ALLOGRAFT REJECTION , 1985, Transplantation.

[128]  Chris Abell,et al.  Drugging challenging targets using fragment-based approaches. , 2010, Current opinion in chemical biology.

[129]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[130]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[131]  Burkhard Rost,et al.  Protein–Protein Interaction Hotspots Carved into Sequences , 2007, PLoS Comput. Biol..

[132]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[133]  J. Hardy,et al.  Dissecting an Allosteric Switch in Caspase-7 Using Chemical and Mutational Probes* , 2009, The Journal of Biological Chemistry.

[134]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[135]  [Amino acid sequence]. , 1970, Deutsche medizinische Wochenschrift.

[136]  W. Leonard,et al.  The Human Interleukin‐2 Receptor: Analysis of Structure and Function , 1986, Immunological reviews.

[137]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[138]  J. Metcalf,et al.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.

[139]  Kendall A. Smith,et al.  Quantitation, Specificity, and Biological Relevance* , 1981 .

[140]  W. Delano Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[141]  Brett A Tounge,et al.  The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.

[142]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[143]  H. Wolfson,et al.  Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .

[144]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[145]  J. Johnston,et al.  Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. , 1994, Science.

[146]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[147]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[148]  W. Delano,et al.  Convergent solutions to binding at a protein-protein interface. , 2000, Science.

[149]  Kendall A. Smith,et al.  The quantal theory of immunity and the interleukin‐2‐dependent negative feedback regulation of the immune response , 2008, Immunological reviews.

[150]  C. Ensor,et al.  Induction Immunosuppression for Orthotopic Heart Transplantation: A Review , 2009, Progress in transplantation.

[151]  K. Christopher Garcia,et al.  The Structure of Interleukin-2 Complexed with Its Alpha Receptor , 2005, Science.

[152]  T. Malek,et al.  The biology of interleukin-2. , 2008, Annual review of immunology.

[153]  D. Barford,et al.  Lining the pockets of kinases and phosphatases. , 2006, Current opinion in structural biology.

[154]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[155]  J. Watson,et al.  Molecular characterization of interleukin 2. , 1982, Immunological reviews.

[156]  P. Nowell Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. , 1960, Cancer research.

[157]  Olivier Sperandio,et al.  Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods , 2010, PLoS Comput. Biol..

[158]  J. Platt,et al.  Escaping from rejection. , 2009, Transplantation.

[159]  Magnus Björsne,et al.  Label-Free Primary Screening and Affinity Ranking of Fragment Libraries Using Parallel Analysis of Protein Panels , 2008, Journal of biomolecular screening.

[160]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[161]  Kristin E. D. Coan,et al.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.

[162]  Jeffrey Aubé,et al.  Structural analysis of β-turn mimics containing a substituted 6-aminocaproic acid linker , 1995 .

[163]  H. Jhoti,et al.  Structure-based screening of low-affinity compounds. , 2002, Drug discovery today.

[164]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[165]  M. Kanehisa,et al.  Structure of the human interleukin-2 receptor gene. , 1985, Science.

[166]  Jianping Ding,et al.  Structural Basis for the Blockage of IL-2 Signaling by Therapeutic Antibody Basiliximab , 2009, The Journal of Immunology.

[167]  S. Rosenberg,et al.  Systemic administration of interleukin-2 in humans. , 1984, Journal of biological response modifiers.

[168]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[169]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[170]  Aurélien Grosdidier,et al.  Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.

[171]  Jian Sun,et al.  Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. , 2009, Biochemistry.

[172]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[173]  Kendall A. Smith,et al.  T‐Cell Growth Factor , 1980, Immunological reviews.

[174]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[175]  R. Nussinov,et al.  The origin of allosteric functional modulation: multiple pre-existing pathways. , 2009, Structure.

[176]  D. Chistiakov,et al.  The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. , 2008, Immunology letters.

[177]  M. Bevan,et al.  Effector and memory CTL differentiation. , 2007, Annual review of immunology.

[178]  Fergal P. Casey,et al.  Discovery of Small Molecule Inhibitors of Protein-Protein Interactions Using Combined Ligand and Target Score Normalization , 2009, J. Chem. Inf. Model..

[179]  Daniel A Erlanson,et al.  Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. , 2008, Bioorganic & medicinal chemistry letters.

[180]  Daniel A Erlanson,et al.  Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. , 2003, Journal of the American Chemical Society.

[181]  W. Leonard,et al.  Cytokines and immunodeficiency diseases: critical roles of the γc‐dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways , 2004, Immunological reviews.

[182]  L. Mario Amzel,et al.  Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.

[183]  Michelle R Arkin,et al.  Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. , 2004, Journal of medicinal chemistry.

[184]  J. Bertoglio,et al.  Recent Advances in the Understanding of Interleukin-2 Signal Transduction , 1998, Journal of Clinical Immunology.

[185]  W. Leonard,et al.  Characterization of the human interleukin-2 receptor gamma chain gene. , 1993, The Journal of biological chemistry.

[186]  T. Waldmann,et al.  High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. , 2008, Journal of autoimmunity.

[187]  T. Waldmann,et al.  Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. , 1989, Transplantation.

[188]  M. Swindells,et al.  Protein clefts in molecular recognition and function. , 1996, Protein science : a publication of the Protein Society.